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Native rat atria1 natriuretic peptide (NANP) was shown to bind with high affinity and to increase intracellular levels 
of cGMP in cultured rat Leydig tumor cells. A linear analog of NANP which lacks the disulfide-linked bridge structure 
also bound with high affinity but did not increase levels of intracellular cGMP or antagonize the increase of this cyclic 
nucleotide by NANP. These data are consistent with the existence of two functional subpopulations of ANP receptors 
on cultured rat Leydig tumor cells; one which is capable of activating guanylate cyclase and one which is not linked 
to this enzyme. 
Atria1 peptide; Linear atria1 natriuretic peptide analog; Guanylate cyclase 
1. INTRODUCTION 
Atria1 natriuretic peptide (ANP), which is syn- 
thesized and secreted by atrial myocytes, has been 
shown to exhibit potent natriuretic, diuretic and 
vasorelaxant activity (review [ 11). The biological 
activities of ANP are manifested through its in- 
teraction with specific high-affinity receptors 
which have been characterized in a variety of dif- 
ferent tissues and cultured cell systems [2]. 
The mechanism of signal transduction following 
ANP receptor occupation is unknown. However, 
ANP has been demonstrated to increase the levels 
of intracellular cGMP in several different cell types 
and tissues exclusively through the activation of 
the particulate form of guanylate cyclase [3]. A 
functional multiplicity of the ANP receptor in 
several cultured vascular cell lines has been 
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demonstrated [4-61. In addition, purification of at 
least two molecular forms of high-affinity ANP- 
binding proteins from vascular [7] and adrenal 
tissue [8] has recently been reported. 
The present study documents the existence of 
high-affinity ANP receptors on a cultured rat 
Leydig tumor cell line. In addition, we present data 
on the dissociation of ANP receptor binding and 
cGMP formation with native and a linear analog 
of ANP which suggests that the ANP receptor 
population on these cells may exist in two different 
functional subpopulations; one which is capable of 
activating guanylate cyclase and one which is not. 
2. MATERIALS AND METHODS 
2.1. Rat Leydig cell culture 
The cells used in these experiments (LC540) were derived 
from a rat Leydig cell testicular tumor and were obtained from 
the American Type Culture Collection (CCL43). Cells were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% heat-inactivated fetal calf serum, 
100 U/ml penicillin, lOO&ml streptomycin, and 10 mM 
Hepes, pH 7.4. All culture media and supplements were pur- 
chased from Gibco. Cells were maintained in a humidified at- 
mosphere of 95% sir/5% CO2 at 37°C. Media were changed 
twice weekly and cells were passaged from confluent cultures at 
a 1: 5 dilution following removal with trypsin/EDTA. 
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2.2. ANP-binding studies 3. RESULTS 
The synthetic ANP peptides which were used in the ex- 
periments are the native 28-amino-acid rat ANP (NANP) and 
a 26-amino-acid linear analog (LANP) which lacks the 
17-membered disulfide-linked bridge structure. Their structures 
are shown below: 
S-L-R-R-S-S-C-F-G-G-R-I-D-R-I-G-A-Q-S-G-L-G-C-N-S-F-R-Y 
1 10 20 
(NAW 
R-R-S-S-F-F-G- G-R-I-D-R-I-G-A-Q-S-G-L-G-F-N-S-F-R-Y 
10 20 
(LAW 
To characterize the interactions of ANP with a 
cultured rat Leydig tumor cell line, 1251-NANP- 
binding experiments were conducted as described 
in section 2. All binding experiments described 
below were performed at 4°C to reduce any possi- 
ble internalization and/or degradation of the la- 
beled ANP peptide which could result in mis- 
interpretation of the binding data. The association 
of “‘1-NANP (50 PM) with confluent cultures of 
rat Leydig tumor cells in monolayer was time- 
dependent with specific binding reaching equilib- 
rium between 90 and 120 min (not shown). Only a 
small rise in the level of non-specific binding was 
observed (5% of total binding at equilibrium). 
NANP was obtained from Bachem while LANP was prepared 
by standard automated solid-phase synthesis using the Applied 
Biosystems instrument 430. Following cleavage from the resin 
the peptide was purified by gel chromatography and preparative 
HPLC (Vydac C4 column). Each peptide was characterized by 
amino acid composition analysis and determined to be greater 
than 98% pure. “‘1-NANP (2000 Ci/mmol) was obtained from 
Amersham. For the binding studies cells were seeded at 1.5 x 
104 cells/cm* in Costar 12-well culture dishes. Triplicate wells 
were used for each experimental point. Cells doubled every 24 h 
following an initial 1 day lag. Confluent cells (4 x 16 
cells/well) were fed on the 4th day with complete medium and 
used on the 5th. Prior to the addition of peptides, each well was 
washed 5 x with 1 ml cold binding medium (DMEM/O.l% 
BSA). Following the addition of ANP peptides, cells were in- 
cubated at 4°C in the same medium for the indicated time. 
Following aspiration of the medium each well was washed 5 
times with 1 ml ice-cold binding medium followed by solubiliza- 
tion in 1 ml of 1 N NaOH. Cell-bound radioactivity was deter- 
mined by gamma counting (LKB) at an efficiency of 78%. 
Binding data were analyzed using the Ligand PC program [9]. 
Cells from three representative wells were removed using Tryp- 
sin/EDTA and counted in a Coulter counter. 
The specific binding of 1251-NANP was 
saturable while non-specific binding increased 
linearly with increasing concentration of labeled 
peptide (fig. 1A). Interpretation of the saturation 
binding data using Scatchard analysis (fig.lA) 
revealed that ‘251-NANP bound to rat Leydig cells 
with an apparent dissociation constant (&) of ap- 
prox. 0.1 nM. The maximum number of 1251- 
NANP-binding sites (Bmax) was calculated to be 
approx. 30000 per cell. The saturation binding 
data best fit a one-site model with no significant 
statistical improvement of the fit obtained by in- 
voking a two-site model. 
2.3. Measurement of intracellular cGMP levels 
Each experimental point was determined in triplicate wells. 
Confluent cultures of cells (see above) in 12-well dishes were 
washed 5 x with binding medium supplemented with 0.1 mM 
isobutylmethylxanthine (at 37°C) and incubated for 5 min at 
37°C prior to the addition of ANP peptides. Following the ad- 
dition of the appropriate peptides the cells were incubated at 
37°C for 10 min. The medium was then aspirated and 1 ml ice- 
cold 10% trichloroacetic acid was added to each well. For an- 
tagonism studies LANP was added to each well at 500 nM 
10 min prior to the addition of NANP. The trichloroacetic acid 
precipitates were removed by centrifugation and the super- 
natants extracted extensively with water-saturated ether and 
dried in vacua. Following reconstitution and acetylation, the 
cGMP content of the supernatants was determined in duplicate 
for each well by cGMP radioimmunoassay (New England 
Nuclear). 
Competition of 1251-NANP (50 PM) binding by 
the corresponding non-radioactive peptide is 
shown in fig.lB. Competition was dose-dependent 
and 95% complete. Scatchard analysis of these 
data revealed virtually identical & and B,,, values 
to those obtained in the saturation binding ex- 
periments shown above. Displacement with a 
26-amino-acid linear analog of NANP (LANP) is 
also shown in fig.lB. This analog lacks the 
17-membered isulfide ring structure found in the 
native peptide (see section 2). As shown in fig.lB, 
this peptide effectively displaced ‘251-NANP 
binding with an estinated competitive inhibition 
constant (Kr) of approx. 0.16 nM. In addition, 
Scatchard analysis of the displacement data for 
LANP revealed a comparable B,, value to that 
obtained for NANP. The same experiment done 
using “‘1-LANP as the tracer ligand yielded results 
similar to those shown in fig.lB (not shown). 
To determine the functional significance of 
ANP binding to rat Leydig cells, intracellular 
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cGMP levels were measured in response to increas- 
ing concentrations of added native and linear ANP 
as described in section 2. cGMP levels increased in 
a dose-dependent manner in response to added 
NANP with an estimated EC50 of approx. 8 nM 
and the maximal response increased 350-fold over 
basal levels (fig.2). In contrast to NANP, however, 
LANP did not substantially stimulate cGMP syn- 
thesis up to a concentration as great as 500 nM 
where a slight increase was noted (fig.2). Since 
LANP bound to rat Leydig cells with a similar af- 
finity to that of NANP (fig.lB), we measured the 
cGMP response to added NANP in the presence of 
500 nM LANP as described in section 2. As shown 
in fig.2, LANP did not significantly alter the dose 
dependence or magnitude of the increase in cGMP 
levels in response to added NANP, suggesting that 
LANP is not a classical competitive antagonist of 
NANP in this assay. 
B 4. DISCUSSION 
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Fig.1. (A) Saturation binding of “‘1-NANP to rat Leydig 
tumor cells. Binding of increasing concentrations of i2’I-NANP 
in the presence (+) and absence (0) of 500 nM non- 
radioactive NANP at 4°C for 90 min was conducted as 
described in section 2. Specific binding (0) was calculated as 
the difference between total and non-specific binding. Each 
point represents the mean of triplicate determinations from one 
of two independent experiments. Also shown is the computer- 
generated Scatchard analysis of the saturation binding data as 
We have demonstrated that a rat Leydig tumor 
cell line expresses high-affinity receptor-binding 
sites for ANP. The binding of ANP to these cells 
was shown to be time dependent and saturable 
with increasing concentrations of NANP. In addi- 
tion, the binding of NANP to the rat Leydig tumor 
cell ANP receptor apparently does not require the 
intact disulfide-bridge structure found in NANP as 
demonstrated by the effective competition by 
LANP on 1251-NANP binding shown in fig.lB. 
Another aspect of this work concerns the effect 
of ANP on the levels of intracellular cGMP in the 
rat Leydig tumor cell line. As shown in fig.2, 
NANP elicited a dramatic dose-dependent rise in 
the levels of intracellular cGMP which was max- 
imally stimulated 350-fold over basal levels. A 
similar effect of ANP on cGMP levels in normal 
determined using the Ligand PC program assuming a one-site 
model [9]. (B) Displacement binding of non-radioactive NANP 
and LANP to rat Leydig tumor cells. Increasing concentrations 
of non-radioactive NANP (0) or LANP (0) were incubated in 
the presence of 50 pM lZ51-NANP at 4°C for 90 min and 
binding determined as described in section 2. Each point 
represents the mean of triplicate determinations from one of 
two independent experiments. The solid lines were determined 
using a non-linear least-square analysis of the binding data. 
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Fig.2. Intracellular cGMP accumulation in cultured rat Leydig 
tumor cells in response to added ANP peptides. Cells were 
incubated with increasing concentrations of either NANP (O), 
LANP (0) or NANP in the presence of 500 nM LANP (0) and 
intracellular cGMP levels determined as described in section 2. 
Results represent he mean of triplicate determinations f SD 
from two independent experiments. 
[ 10,l l] and tumor-derived [121 murine Leydig cells 
in culture has been reported. In contrast to NANP, 
the ability of a linear analog (LANP) to stimulate 
cGMP synthesis in these cells was dramatically at- 
tenuated (see fig.2). In the presence of this linear 
peptide at a concentration of 500 nM (3000-times 
the Ki determined from the displacement binding 
studies; fig.lB), the cGMP effect elicited by 
NANP was not significantly altered (fig.2). This 
suggests that LANP does not act as a competitive 
antagonist of NANP in this assay but, instead, ap- 
pears to be preferentially binding to a predominant 
high-affinity ANP receptor not coupled to the for- 
mation of cGMP. The binding of NANP not only 
to this ‘cGMP uncoupled’ form of the ANP recep- 
tor but also to a form which results in the forma- 
tion of cGMP apparently leads to the observed 
dissociation of high-affinity receptor binding and 
cGMP formation shown in figs IA and 2. 
The existence of two functional subtypes of the 
ANP receptor has been demonstrated by other in- 
vestigators using cultured vascular endothelial 
[4,5] as well as smooth muscle cells [6]. In addi- 
tion, it appears that two molecular forms of high- 
affinity ANP receptors exist in adrenal tissue, one 
which can catalyze the formation of cGMP and 
another which cannot [8]. Moreover, a putative 
function for the cGMP uncoupled form of the 
ANP receptor has been recently proposed [ 131. We 
have shown that the same phenomenon exists in a 
cell type not normally associated with the actions 
of ANP. In addition, we have demonstrated that 
the 17-membered ring structure found in NANP, 
although not required for high-affinity binding to 
the putative cGMP-uncoupled form of the ANP 
receptor, appears to be extremely important for 
high-affinity binding and subsequent efficient 
coupling of the second ANP receptor subtype to 
guanylate cyclase. These results are not consistent 
with the report of Pandey et al. [14] which clearly 
demonstrates a single form of the ANP receptor in 
a tumor-derived murine Leydig cell line. We 
believe this is due to the absence of the cGMP- 
uncoupled form of the ANP receptor in this par- 
ticular cell line. However, a definitive conclusion 
awaits a direct comparison of both cell lines using 
the experimental protocols described above. 
acknowledgements: We would like to thank Dr Mark Polokoff 
for critically evaluating the manuscript and Carole Hannan for 
excellent secretarial support. 
REFERENCES 
[l] Genest, J. and Cantin, M. (1987) Circulation 75, 
I-118-124. 
[2] Jacobs, J.W., Vlasuk, G.P. and Rosenblatt, M. (1987) in: 
Endocrinology and Metabolism Clinics of North America 
(Rosenblatt, M. and Jacobs, J.W. eds) ~01.16, pp.63-77, 
Saunders, Philadelphia. 
[3] Leitman, DC. and Murad, F. (1987) in: Endocrinoloav __ 
[41 
m!Sl 
WI 
171 
PI 
[71 
PI 
and Metabolism Clinics of North America (Rosenblatt, 
M. and Jacobs, J.W. eds) ~01.16, pp.79-105, Saunders, 
Philadelphia. 
Leitman, D.C. and Murad, F. (1987) B&him. Biophys. 
Acta 885, 74-79. 
Leitman, D.C., Andresen, J.W., Kuno, T., Kaminsky, 
Y., Chang, J.K. and Murad, F. (1986) J. Biol. Chem. 261, 
11650-11655. 
Scarborough, R.M., Schenk, D.B., McEnroe, GA., 
Arfsten, A., Kang, L.L., Schwartz, K. and Lewicki, J.A. 
(1986) J. Biol. Chem. 261, 12960-12964. 
Schenk, D.B., Phelps, M.N., Porter, J.G., Fuller, F., 
Cordell, B. and Lewicki, J.A. (1987) Proc. Natl. Acad. 
Sci. USA 84, 1521-1525. 
Takayanagi, R., Inagami, I., Snajdar, R.M., Imada, T., 
Tamura, M. and Misono, K.S. (1987) J. Biol. Chem. 262, 
12104-12113. 
Waldman, S.A., Rapoport, R.M. and Murad, F. (1984) J. 
Biol. Chem. 259, 14332-14334. 
Winquist, R.J., Faison, E.P., Waldman, S.A., Schwartz, 
K., Murad, F. and Rapoport, R.M. (1984) Proc. Natl. 
Acad. Sci. USA 81, 7661-7664. 
293 
Vo@me 228, number 2 FEBS LETTERS February 1988 
[9] Munson, P.J. and Rodbard, D. (1984) Computers in 
Endocrinology, pp.117-145, Raven, New York. 
[lo] Mukhopadhyay, A.K., Schumacher, M. and 
Leidenberger, F.A. (1986) Biochem. J. 239, 463-467. 
[l l] Pandey, K.N., Parlou, S.N., Kovacs, W.J. and Inagami, 
T. (1986) Biochem. Biophys. Res. Commun. 138, 
399-404. 
[12] Pandey, K.N., Kovacs, W.J. and Inagami, T. (1985) Bio- 
them. Biophys. Res. Commun. 133, 800-806. 
[13] Maack, T., Suzuki, M., Almedia, F.A., Nussenzveiz, D., 
Scarborough, R.M., McEnroe, G.A. and Lewicki, J.A. 
(1987) Science 238, 675-678. 
[14] Pandey, K.N., Inagami, T. and Misono, K.S. (1986) 
Biochemistry 25, 8467-8472. 
294 
